LLY

1,152.41

-2.04%↓

JNJ

231.8

-0.62%↓

ABBV

223.9

-0.76%↓

UNH

410.6

+2.54%↑

MRK

118.89

-2.67%↓

LLY

1,152.41

-2.04%↓

JNJ

231.8

-0.62%↓

ABBV

223.9

-0.76%↓

UNH

410.6

+2.54%↑

MRK

118.89

-2.67%↓

LLY

1,152.41

-2.04%↓

JNJ

231.8

-0.62%↓

ABBV

223.9

-0.76%↓

UNH

410.6

+2.54%↑

MRK

118.89

-2.67%↓

LLY

1,152.41

-2.04%↓

JNJ

231.8

-0.62%↓

ABBV

223.9

-0.76%↓

UNH

410.6

+2.54%↑

MRK

118.89

-2.67%↓

LLY

1,152.41

-2.04%↓

JNJ

231.8

-0.62%↓

ABBV

223.9

-0.76%↓

UNH

410.6

+2.54%↑

MRK

118.89

-2.67%↓

Strona główna・Stock List・Guardant Health Inc

Guardant Health Inc

Open

SectorHealthcare

126.58 -1.08

Buy Sell

Overview

Share price change

24h

Current

Min

124

Max

128.83

Key metrics
By Trading Economics
Income	16M -112M
Sales	20M 302M
EPS	-0.45
Profit margin	-37.152
Employees	2,490
EBITDA	18M -101M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+12.2% upside

Dividends
By Dow Jones
Next Earnings	29 lip 2026

Market Stats
By TradingEconomics
Market Cap	5B 17B
Previous open	127.66
Previous close	126.58

News Sentiment

By Acuity

50%

161 / 344 Ranking in Healthcare

Guardant Health Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

8 cze 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 cze 2026, 15:41 UTC

Major Market Movers

American Battery Shares Jump on Energy Department Victory

8 cze 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 cze 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 cze 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 cze 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

8 cze 2026, 21:57 UTC

Acquisitions, Mergers, Takeovers

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 cze 2026, 21:56 UTC

Acquisitions, Mergers, Takeovers

Salesforce Agrees to Buy m3ter

8 cze 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 cze 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 cze 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 cze 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

8 cze 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 cze 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 cze 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 cze 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 cze 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 cze 2026, 16:55 UTC

Acquisitions, Mergers, Takeovers

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 cze 2026, 16:54 UTC

Acquisitions, Mergers, Takeovers

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 cze 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 cze 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 cze 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

8 cze 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 cze 2026, 16:03 UTC

Acquisitions, Mergers, Takeovers

Orange Bought Stake From Lorca

8 cze 2026, 16:01 UTC

Acquisitions, Mergers, Takeovers

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 cze 2026, 16:01 UTC

Acquisitions, Mergers, Takeovers

Orange Acquires 100% Ownership of MasOrange

8 cze 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

8 cze 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 cze 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 cze 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

Peer Comparison

Price change

Guardant Health Inc Forecast

Price Target

By TipRanks

12.2% upside

12 Months Forecast

Average 140.94 USD 12.2%

High 175 USD

Low 120 USD

Based on 19 Wall Street analysts offering 12 month price targets forGuardant Health Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

19 ratings

Buy

Hold

Sell

Based on 19 analysts giving stock ratings to Guardant Health Inc - Dist in the past 3 months.

Sentiment

By Acuity

161 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.